Sensus Healthcare, Inc. (NASDAQ:SRTS) had its target price raised by investment analysts at Maxim Group from $6.50 to $7.50 in a research report issued on Friday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 28.21% from the stock’s current price.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.08. Sensus Healthcare had a negative return on equity of 16.40% and a negative net margin of 13.31%. The company had revenue of $4.97 million for the quarter, compared to analyst estimates of $4.50 million.

COPYRIGHT VIOLATION NOTICE: “Sensus Healthcare, Inc. (SRTS) Price Target Raised to $7.50 at Maxim Group” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/03/sensus-healthcare-inc-srts-price-target-raised-to-7-50-at-maxim-group.html.

In other Sensus Healthcare news, insider Kalman Fishman sold 5,378 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $6.00, for a total value of $32,268.00. Following the transaction, the insider now directly owns 990,845 shares of the company’s stock, valued at $5,945,070. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph C. Sardano sold 9,625 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $6.00, for a total value of $57,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,625,821 shares in the company, valued at $9,754,926. The disclosure for this sale can be found here. Insiders sold 98,551 shares of company stock worth $591,306 over the last three months. 41.70% of the stock is currently owned by corporate insiders.

A hedge fund recently bought a new stake in Sensus Healthcare stock. B. Riley Financial Inc. purchased a new position in Sensus Healthcare, Inc. (NASDAQ:SRTS) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 104,794 shares of the company’s stock, valued at approximately $421,000. B. Riley Financial Inc. owned approximately 0.77% of Sensus Healthcare as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 8.09% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy.

Receive News & Ratings for Sensus Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.